Abstract

BackgroundA new, simple and accurate stability-indicating reverse phase high performance liquid chromatography method was developed and validated during the early stage of drug development of an oral lyophilizate dosage form of cetirizine dihydrochloride.MethodsFor RP-HPLC analysis it was used an Eclipse XDB C8 column 150 mm × 4.6 mm, 5 μm (Agilent columns, Barcelona, Spain) as the stationary phase with a mobile phase consisted of a mixture of 0.2 M K2HPO4 pH 7.00 and acetonitrile (65:35, v/v) at a flow rate of 1 mL min −1. Detection was performed at 230 nm using diode array detector. The method was validated in accordance with ICH guidelines with respect to linearity, accuracy, precision, specificity, limit of detection and quantification.ResultsThe method results in excellent separation between the drug substance and its stress-induced degradation products. The peak purity factor is >950 for the drug substance after all types of stress, which confirms the complete separation of the drug substance peak from its stress induced degradation products.Regression analysis showed r2 > 0.999 for cetirizine dihydrochloride in the concentration range of 650 μg mL −1 to 350 μg mL−1 for drug substance assay and a r2 > 0.999 in the concentration range of 0.25 μg mL−1 to 5 μg mL−1 for degradation products. The method presents a limit of detection of 0.056 μg mL −1 and a limit of quantification of 0.25 μg mL−1. The obtained results for precision and accuracy for drug substance and degradation products are within the specifications established for the validation of the method.ConclusionsThe proposed stability-indicating method developed in the early phase of drug development proved to be a simple, sensitive, accurate, precise, reproducible and therefore useful for the following stages of the cetirizine dihydrochloride oral lyophilizate dosage form development.

Highlights

  • A new, simple and accurate stability-indicating reverse phase high performance liquid chromatography method was developed and validated during the early stage of drug development of an oral lyophilizate dosage form of cetirizine dihydrochloride

  • HPLC method development As an early stage study of drug development, our goal was to acknowledge all possible degradation products (DE) generated under stress conditions for Cetirizine dihydrochloride (CTZ)

  • The information acquired in the early stage of the study will lead us to a better understanding of the drug substance (DS) itself and the possible DE that we may find during the step of the oral lyophilized development study

Read more

Summary

Introduction

A new, simple and accurate stability-indicating reverse phase high performance liquid chromatography method was developed and validated during the early stage of drug development of an oral lyophilizate dosage form of cetirizine dihydrochloride. Eur. method for CTZ [17] The latter was discarded due to the use of a normal phase chromatographic column and mobile phase that used much organic solvent (acetonitrile, not very cost-effective). We have developed a reverse-phase high performance liquid chromatography (RP-HPLC) method by studying the effect of the stationary phase (C18 or C8 analytical columns) on peak resolution, the influence of pH -mobile phasewhen adjusting the desired retention time (tR) for the DS. The aim of this study is to determine all possible DE generated under stress conditions, by developing and validating a stability-indicating RP-HPLC method for cetirizine dihydrochloride in the early stage of drug development of an oral lyophilizate

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call